Oragenics Inc (OGEN)

$0.59 -0.01 (-1.16%)
Market Cap 2.68M
Revenue (ttm) 0.00
Net Income (ttm) -9.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,100
Avg Vol 62,488
Day's Range N/A - N/A
Shares Out 4.51M
Stochastic %K 27%
Beta 1.27
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Address:
9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States
RocketQueen
RocketQueen Jun. 7 at 6:39 PM
$OGEN crushing $SIGY dilution and near certain failure of the nasal scam in the phase II clinical trials to look forward to here.
0 · Reply
RocketQueen
RocketQueen Jun. 6 at 8:56 PM
$OGEN So, basically, Jake had no faith in his nasal scam product: "The money was purportedly for the development of a pharmaceutical concussion treatment. But, prosecutors said in a bill of information that VanLandingham misused “a substantial amount of these funds for his personal benefit, including, but not limited to, gambling and paying off personal debts,” according to the bill".--AP
0 · Reply
RocketQueen
RocketQueen Jun. 6 at 8:39 PM
$OGEN Not accumulating any shares here ever. https://apnews.com/article/mississippi-welfare-fraud-brett-favre-concussions-vanlandingham-a9d7dc89a20f905571a642957f7b2d08
1 · Reply
NMax
NMax Jun. 5 at 9:02 PM
$OGEN Loving this accumulation!! 😍 See you all next week for more more more!!! Ok Racketeerqueem, the mic is yours for your weekend fraudulent begging to cover your short position lolol. Make sure to borrow enough shares by Monday cuz I'm ready to load the F up!!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 5 at 8:33 PM
$OGEN @SXCross the lead product is valued at zero because it was developed by a con artist and 95% probability of failure in human trial.
1 · Reply
SXCross
SXCross Jun. 5 at 4:50 PM
$OGEN I will continue to buy. The share price is below the cash position. The product candidate is valued at zero.
0 · Reply
NMax
NMax Jun. 5 at 4:11 PM
$OGEN continuing to accumulate!! Loving it!! 😁 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 5 at 3:21 PM
$OGEN Self explanatory... https://www.tallahassee.com/story/news/local/2024/07/30/former-fsu-researcher-pleads-guilty-to-wire-fraud-in-welfare-scandal/74589367007/
0 · Reply
NMax
NMax Jun. 5 at 12:17 AM
$OGEN I got all the time in existence. 😉 Continuing to accumulate!!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 4 at 11:51 PM
$OGEN scam and fraud company. Keep accumulating here and this is where your hard earned money will end up.
0 · Reply
Latest News on OGEN
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

May 19, 2026, 8:45 AM EDT - 19 days ago

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

ORAGENICS PROVIDES INVESTOR UPDATE

May 18, 2026, 8:30 AM EDT - 20 days ago

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

May 5, 2026, 8:30 AM EDT - 4 weeks ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

2026-04-20T14:01:13.000Z - 6 weeks ago

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Apr 13, 2026, 8:30 AM EDT - 7 weeks ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics receives audit opinion with going concern explanation

2026-03-25T22:35:16.000Z - 2 months ago

Oragenics receives audit opinion with going concern explanation

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Mar 25, 2026, 6:30 PM EDT - 2 months ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics files annual report on Form 10-K

2026-03-17T12:49:42.000Z - 2 months ago

Oragenics files annual report on Form 10-K

Oragenics initiates Phase IIa clinical trial site activation

2026-03-12T12:48:45.000Z - 3 months ago

Oragenics initiates Phase IIa clinical trial site activation

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Mar 12, 2026, 8:30 AM EDT - 3 months ago

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Oragenics explores potential acquisition of additional assets in CNS space

2026-03-11T12:45:33.000Z - 3 months ago

Oragenics explores potential acquisition of additional assets in CNS space

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Mar 11, 2026, 8:30 AM EDT - 3 months ago

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

2026-03-10T12:42:00.000Z - 3 months ago

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Mar 10, 2026, 8:30 AM EDT - 3 months ago

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Oragenics previews targeted milestones for 2026

2026-02-09T13:46:12.000Z - 4 months ago

Oragenics previews targeted milestones for 2026

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Feb 9, 2026, 8:30 AM EST - 4 months ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

2026-02-03T13:40:46.000Z - 4 months ago

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Feb 3, 2026, 8:30 AM EST - 4 months ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Oragenics files $100M mixed securities shelf

2026-01-22T21:15:38.000Z - 4 months ago

Oragenics files $100M mixed securities shelf

Oragenics Q3 2025 Shareholder Update

Nov 12, 2025, 8:30 AM EST - 7 months ago

Oragenics Q3 2025 Shareholder Update

Oragenics regains compliance with NYSE

2025-10-21T12:15:12.000Z - 8 months ago

Oragenics regains compliance with NYSE

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 21, 2025, 8:00 AM EDT - 8 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics, Receptor.AI partner to accelerate pipeline development

2025-10-07T13:20:29.000Z - 8 months ago

Oragenics, Receptor.AI partner to accelerate pipeline development

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oct 7, 2025, 8:30 AM EDT - 8 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

2025-08-11T12:50:19.000Z - 10 months ago

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 10 months ago

Oragenics Q2 2025 Shareholder Update

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

2025-07-31T12:52:03.000Z - 11 months ago

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

2025-07-16T12:45:56.000Z - 11 months ago

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 11 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Oragenics Completes Approximately $16.5 Million Offering

Why Is Oragenics Stock (OGEN) Down 55% Today?

2025-07-02T01:00:00.000Z - 1 year ago

Why Is Oragenics Stock (OGEN) Down 55% Today?

Oragenics trading resumes

2025-07-01T12:50:11.000Z - 1 year ago

Oragenics trading resumes

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

2025-07-01T12:41:48.000Z - 1 year ago

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics trading halted, news pending

2025-07-01T12:05:53.000Z - 1 year ago

Oragenics trading halted, news pending

Oragenics trading resumes

2025-06-03T13:40:31.000Z - 1 year ago

Oragenics trading resumes

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 2 years ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 2 years ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 2 years ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 2 years ago

Oragenics Announces Proposed Public Offering

RocketQueen
RocketQueen Jun. 7 at 6:39 PM
$OGEN crushing $SIGY dilution and near certain failure of the nasal scam in the phase II clinical trials to look forward to here.
0 · Reply
RocketQueen
RocketQueen Jun. 6 at 8:56 PM
$OGEN So, basically, Jake had no faith in his nasal scam product: "The money was purportedly for the development of a pharmaceutical concussion treatment. But, prosecutors said in a bill of information that VanLandingham misused “a substantial amount of these funds for his personal benefit, including, but not limited to, gambling and paying off personal debts,” according to the bill".--AP
0 · Reply
RocketQueen
RocketQueen Jun. 6 at 8:39 PM
$OGEN Not accumulating any shares here ever. https://apnews.com/article/mississippi-welfare-fraud-brett-favre-concussions-vanlandingham-a9d7dc89a20f905571a642957f7b2d08
1 · Reply
NMax
NMax Jun. 5 at 9:02 PM
$OGEN Loving this accumulation!! 😍 See you all next week for more more more!!! Ok Racketeerqueem, the mic is yours for your weekend fraudulent begging to cover your short position lolol. Make sure to borrow enough shares by Monday cuz I'm ready to load the F up!!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 5 at 8:33 PM
$OGEN @SXCross the lead product is valued at zero because it was developed by a con artist and 95% probability of failure in human trial.
1 · Reply
SXCross
SXCross Jun. 5 at 4:50 PM
$OGEN I will continue to buy. The share price is below the cash position. The product candidate is valued at zero.
0 · Reply
NMax
NMax Jun. 5 at 4:11 PM
$OGEN continuing to accumulate!! Loving it!! 😁 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 5 at 3:21 PM
$OGEN Self explanatory... https://www.tallahassee.com/story/news/local/2024/07/30/former-fsu-researcher-pleads-guilty-to-wire-fraud-in-welfare-scandal/74589367007/
0 · Reply
NMax
NMax Jun. 5 at 12:17 AM
$OGEN I got all the time in existence. 😉 Continuing to accumulate!!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 4 at 11:51 PM
$OGEN scam and fraud company. Keep accumulating here and this is where your hard earned money will end up.
0 · Reply
NMax
NMax Jun. 4 at 7:08 PM
$OGEN Continuing to accumulate. If you don't believe me at this point then you're a world class idiot. Yes, Racketqueem is that idiot. That idiot claims to have sold in March of 2025, yet obsessively posts manipulative bearish articles from years ago every single day. And obsesses over me and how many shares I have. Its funny but sad. Your short position is f'd racketqueem. Thank you for the cheap shares lolol!!! Contunuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 4 at 5:33 PM
$OGEN $0.00 Revenue Per Employee...Actually, it should read 0 employees and 0 revenue. Nothing left here but a greedy and corrupt board using Janet as a voice for a now obviously failed company. @NMax is *not accumulating any shares as no sane human being would continuously do that through 2 reverse splits. Ignore him.
0 · Reply
NMax
NMax Jun. 4 at 4:38 PM
$OGEN contunuing to accumulate!! Loving it!!! 😁 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 4 at 4:32 PM
$OGEN near zero change this will pass phase II clinical trials since there is no established scientific basis for why the nasal scam would work in humans. Also, consider the inventor literally lied about everything including his academic credentials. He's currently awaiting a prison sentence for fraud. The dude lied about the lies that he lied about.
0 · Reply
NMax
NMax Jun. 4 at 3:52 PM
$OGEN continuing to accumulate!! 😁 Loving it!!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 4 at 3:25 AM
$OGEN after 10 years of no productivity, the gig is up here. It's time to start winding things down and shelve this scam for good. They have produced no products, and done zero to benefit society or shareholders.
0 · Reply
NMax
NMax Jun. 3 at 9:34 PM
$OGEN Continuing to accumulate!! 😁 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 3 at 2:40 PM
$OGEN scan and fraud company. AI is booming now. If you sell whatever you have left now, you can probably >1000% the remains. That's basically what I did last year. If you stay here, you'll multiply losses and not recover ever.
0 · Reply
profitingstocks
profitingstocks Jun. 3 at 10:36 AM
$OGEN with all the real companies out there with stocks that are consistently performing, why would anyone want to buy some crap like this?
1 · Reply
NMax
NMax Jun. 3 at 3:06 AM
$OGEN lol, bought more as well 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 2 at 8:08 PM
$OGEN not clear if something like this nasal scam would be any better than taking ibuprofen or Tylenol. 90% probability they fail phase II trials. That's why another garbage can pivot is in play. Do they even have a real physical address? If you look up their advertised listing in google maps, it just brings up public dumpsters, alleys and parking garages.
0 · Reply
SXCross
SXCross Jun. 2 at 6:20 PM
$OGEN i bought more
2 · Reply